Xeris Biopharma Exceeds Full-Year 2025 Revenue Guidance with Strong Preliminary Results
Summary
Xeris Biopharma reported preliminary full-year 2025 revenue of $292 million, exceeding its guidance and reflecting 44% year-over-year growth, alongside positive Adjusted EBITDA and strengthened IP.
Key Events
-
Exceeds Full-Year Revenue Guidance
Reported preliminary total revenue of $292 million for full-year 2025, surpassing the guidance range of $285-$290 million.
-
Strong Year-Over-Year Growth
Full-year 2025 revenue reflects a 44% increase compared to the prior year, driven by strong product performance.
-
Key Product Performance
Recorlev® net revenue reached $139 million for the full year, with approximately 700 patients on therapy. Gvoke® revenue grew over 13%, and Keveyis® saw a growing patient base.
-
Positive Adjusted EBITDA
The company achieved positive Adjusted EBITDA in every quarter of 2025.
Analysis
Xeris Biopharma Holdings, Inc. announced preliminary financial results for the fourth quarter and full year 2025, reporting total revenue of $292 million, which surpassed its previous guidance range of $285-$290 million. This performance represents a significant 44% year-over-year growth, driven by strong contributions from its key products, Recorlev®, Gvoke®, and Keveyis®. The company also achieved positive Adjusted EBITDA in every quarter and strengthened its intellectual property portfolio, indicating robust operational execution and a positive outlook for sustained growth.
At the time of this filing, XERS was trading at $7.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.14 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.